Altamira Therapeutics shares are trading higher Monday after the company announced that it has entered into a collaboration agreement with Univercells Group to evaluate the use of the company's proprietary SemaPhore platform for the delivery of mRNA vaccines. Under the terms of the agreement, Univercells will test a proprietary mRNA vaccine delivered with Altamira's SemaPhore nanoparticle platform. If the experiments are successful, the companies intend to discuss and negotiate a commercial agreement for the development and manufacturing of nanoparticle-based mRNA vaccines using Univercells' production platform.